Jacques Banville

USPTO Granted Patents = 27 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 5.3

ph-index = 8

Forward Citations = 218(Granted Patents)

Location History:

St. Hubert, CA (1996 - 2004)
St-Hubert, CA (2001 - 2011)
Montreal, CA (2019)
Saint-Hubert, CA (2017 - 2024)

Company Filing History:

24 out of 3,681

Bristol-myers Squibb Compnay

patents

8 out of 183

Universitéde Montreal

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479842 - Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease (2025-11-25),

2. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2024-09-10),

3. 12060353 - Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease (2024-08-13),

4. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

5. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

6. 10214544 - Imidazopyridazine and imidazothiadiazole compounds (2019-02-26),

7. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-08-14),

8. 9862730 - Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-01-09),

9. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2017-06-27),

10. 8039458 - HIV integrase inhibitors (2011-10-18),

11. 7893055 - HIV integrase inhibitors (2011-02-22),

12. 7511037 - N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor (2009-03-31),

13. 7494984 - Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors (2009-02-24),

14. 7192948 - Bicyclic heterocycles as HIV integrase inhibitors (2007-03-20),

15. 7176196 - Bicyclic heterocycles as HIV integrase inhibitors (2007-02-13),

Title: Jacques Banville - Inventor from St-Hubert, CA

Introduction: Jacques Banville is a renowned inventor hailing from St-Hubert, Canada. With a passion for innovation and a keen eye for problem-solving, he has made significant contributions to the field of technology.

Latest Patents: Jacques Banville holds several patents in various technological domains, including telecommunications, renewable energy, and consumer electronics. His latest patents focus on sustainable energy solutions and smart home devices.

Career Highlights: Throughout his career, Jacques Banville has worked with leading tech companies to develop cutting-edge products. His innovative ideas have led to the creation of groundbreaking technologies that have improved the lives of many.

Collaborations: Jacques Banville has collaborated with top researchers, engineers, and designers to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Jacques Banville's dedication to innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of technology. His inventive spirit continues to inspire others to push the boundaries of what is possible in the realm of inventions.

This text is generated by artificial intelligence and may not be accurate.